Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 56,618 shares, a decline of 78.8% from the April 15th total of 267,352 shares. Based on an average trading volume of 158,455 shares, the short-interest ratio is presently 0.4 days. Approximately 2.0% of the shares of the stock are short sold.

Institutional Trading of Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 75.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Cyclerion Therapeutics Stock Down 1.6%

CYCN stock traded down $0.05 during trading on Wednesday, hitting $3.13. The company had a trading volume of 142,964 shares, compared to its average volume of 122,523. The firm has a 50-day moving average price of $2.63 and a 200-day moving average price of $1.89. Cyclerion Therapeutics has a 12 month low of $1.03 and a 12 month high of $8.48. The stock has a market cap of $13.55 million, a price-to-earnings ratio of -2.30 and a beta of 1.80.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($17.20) by $16.44. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 58.21%. Equities analysts expect that Cyclerion Therapeutics will post -1.2 EPS for the current year.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.